Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AKTX 101

Next Previous
Drug Profile

AKTX 101

Alternative Names: AKTX-101; Anti TROP2 ADC - Akari Therapeutics; Anti TROP2 antibody drug conjugate - Akari Therapeutics; Torpedo™; Trop2 PH1 ADC - Akari Therapeutics

Latest Information Update: 09 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peak Bio
  • Developer Akari Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action DNA topoisomerase I inhibitors; RNA splicing modulators; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 04 Dec 2025 Akari Therapeutics plans a clinical trials for Cancer in the fourth quarter of 2026
  • 09 Oct 2025 Akari Therapeutics files for patent protection with the United States Patent and Trademark Office (USPTO) for its novel PH1 spliceosome-modulating payload and combination immuno-oncology therapies in the USA
  • 24 Sep 2025 Pharmacodynamics data from preclinical studies in Solid tumours released by Akari Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top